Effect of Passive Immunization on the Progression of Alzheimer's Disease: LY2062430 Versus Placebo
Effect of Passive Immunization on the Progression of Alzheimer's Disease: LY2062430 Versus Placebo
Alzheimer's disease (AD) is an age-related degenerative disorder of the brain, characterized by progressive decline in cognitive function and ability to perform activities of daily living, and ultimately can lead to death due to complications of the disease. AD is thought to be caused by an excess of A-Beta amyloid, a sticky protein in the brain that forms amyloid plaques. Treatments that slow the synthesis or deposition of A-Beta amyloid, or that increase clearance, might be expected to slow the progression of AD.
LY2062430 (solanezumab) is a humanized anti-A Beta peptide immunoglobulin G-1 (IgG1) monoclonal antibody being developed for the treatment of AD. The primary hypothesis being tested is that LY2062430 will slow cognitive and functional decline in AD as compared with placebo. Each patient's participation will last approximately 19 months. Patients taking approved AD medications may participate in this study and continue taking these medications during the study.
Inclusion Criteria:
Exclusion Criteria:
Tucson, Arizona 85741, United States
Los Angeles, California 90033, United States
San Diego, California 92103, United States
San Francisco, California 94109, United States
Santa Monica, California 90404, United States
New Haven, Connecticut 06510, United States
Miami, Florida 33137, United States
Tampa Bay, Florida 33613, United States
Hattiesburg, Mississippi 39401, United States
Creve Coeur, Missouri 63141, United States
Kansas City, Missouri 64114, United States
Amherst, New York 14226, United States
Staten Island, New York 10312, United States
Portland, Oregon 97210, United States
San Antonio, Texas 78229, United States
Seattle, Washington 98108, United States
Bankstown, New South Wales 2200, Australia
Darlinghurst, New South Wales 2010, Australia
Gosford, New South Wales 2250, Australia
Kogarah, New South Wales 2217, Australia
Chermside, Queensland 4032, Australia
Toowoomba, Queensland 4650, Australia
Box Hill, Victoria 3128, Australia
Glen Iris, Victoria 3146, Australia
Heidelberg Heights, Victoria 3081, Australia
Melbourne, Victoria 3004, Australia
Subiaco, Western Australia 6008, Australia
Aix-en-Provence, 13100, France
Paris, 75475, France
Rennes, 35000, France
Strasbourg, 67091, France
Toulouse, 31300, France
Berlin, D-12200, Germany
Hamburg, 22307, Germany
Hanover, 30559, Germany
Mannheim, 68165, Germany
Marburg, 35033, Germany
München, BY 80336, Germany
München, D-81675, Germany
Regensburg, 93042, Germany
Biella, 13900, Italy
Boggiovara, 41100, Italy
Cassino, 03043, Italy
Chieti, 66013, Italy
Genova, 16128, Italy
Lido di Camaiore, 55043, Italy
Milan, 20132, Italy
Rome, 00179, Italy
Ehime, 791-0295, Japan
Fukuoka, 816-0864, Japan
Hyōgo, 514-8507, Japan
Kanagawa, 247-0072, Japan
Kyoto, 606-0851, Japan
Osaka, 558-0056, Japan
Shizuoka, 424-0911, Japan
Tokyo, 173, Japan
Bialystok, 15-617, Poland
Bydgoszcz, 85-796, Poland
Gliwice, 44-100, Poland
Katowice, 40-588, Poland
Krakow, 31-530, Poland
Lublin, 20-090, Poland
Warsaw, 02-777, Poland
Chelyabinsk, 454091, Russia
Rostov-on-Don, 344010, Russia
Saint Petersburg, 190021, Russia
Yekaterinburg, 620030, Russia
Incheon, 400-711, South Korea
Seongnam-si, 463-707, South Korea
Seoul, 143-729, South Korea
Suwon, 443-721, South Korea
Barcelona, 08014, Spain
Getafe, 28905, Spain
Madrid, 28034, Spain
Plasencia, 10600, Spain
Terrassa, 0821, Spain
Jönköping, 551 85, Sweden
Kalmar, 39185, Sweden
Lund, 22241, Sweden
Malmö, 20502, Sweden
Mölndal, 43135, Sweden
Stockholm, 14186, Sweden
Umeå, 901 85, Sweden
Kaohsiung City, 807, Taiwan
Niao Sung Hsiang, 83301, Taiwan
Taichung, 404, Taiwan
Taipei, 112, Taiwan
Taoyuan, 333, Taiwan
Yung-Kang, Tainan, 710, Taiwan
Uckfield, E Susx TN225AW, United Kingdom
Scotland, Glasgow G20 0XA, United Kingdom
London, Greater London N195NX, United Kingdom
Camberwell, London SE5 8AF, United Kingdom
Sheffield, Syorks S57JT, United Kingdom